InvestorsHub Logo
Followers 0
Posts 11184
Boards Moderated 1
Alias Born 02/17/2008

Re: None

Thursday, 08/17/2017 1:38:42 PM

Thursday, August 17, 2017 1:38:42 PM

Post# of 33254
ENDV - Only biotech currently developing a non-invasive, non-pharmacological approach for the treatment of NASH, an inflammatory condition in the liver due to a buildup of fat that can lead to cirrhosis and liver failure if left untreated
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENDV News